Obalon therapeutics inc (OBLN)
Income statement / TTM
Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Sep'15
Revenue:
Revenue

3,300

4,620

7,287

9,601

9,101

0

0

0

-

0

0

-

-

-

-

-

-

Cost of revenue

-

0

0

0

-

0

0

0

-

0

0

-

-

-

-

-

-

Revenue

-

-

-

-

-

-

-

-

-

-

-

1,472

0

0

0

0

-

Revenue, related party

-

-

-

-

-

-

-

-

-

-

-

-

3,393

3,714

0

0

0

Revenues

-

-

-

-

-

-

-

-

-

-

-

-

3,393

3,714

0

0

0

Cost of revenue

-

-

-

-

-

-

-

-

-

-

-

3,010

2,809

2,582

0

0

0

Gross profit

331

703

2,351

3,644

3,678

5,136

5,040

5,013

5,085

2,996

1,652

786

584

1,132

0

0

0

Operating expenses:
Research and development

6,893

7,739

8,933

10,497

10,697

11,048

11,478

10,886

10,647

10,563

9,934

9,760

9,872

10,468

0

0

0

Selling, general and administrative

16,668

19,879

23,226

26,144

29,946

32,315

34,292

32,895

28,829

24,436

19,035

14,778

10,217

6,005

0

0

0

Total operating expenses

23,561

27,618

32,159

36,641

40,643

43,363

45,770

43,781

39,476

34,999

28,969

24,538

20,089

16,473

0

0

0

Loss from operations

-23,230

-26,915

-29,808

-32,997

-36,965

-38,227

-40,730

-38,768

-34,391

-32,003

-27,317

-23,752

-19,505

-15,341

0

0

0

Interest expense, net

-385

-510

-617

-379

-226

-189

-140

-118

-135

-162

-276

-384

-477

-567

0

0

0

Loss from change in fair value of warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

466

592

0

0

0

Other expense

-61

-94

-133

-168

-189

-328

-299

-260

-239

-59

-52

-6

-19

-34

0

0

0

Net Income (Loss) Attributable to Parent

-23,676

-27,519

-30,558

-33,544

-37,380

-38,744

-41,169

-39,146

-34,765

-32,140

-28,230

-24,631

-20,467

-16,534

0

0

0

Other Comprehensive Income (Loss), Net of Tax

0

2

-1

-1

5

2

20

20

-4

-9

-23

-17

-1

3

0

0

0

Net loss and comprehensive loss

-23,676

-27,517

-30,559

-33,545

-37,375

-38,742

-41,149

-39,126

-34,769

-32,149

-28,253

-24,648

-20,468

-16,531

0

0

0

Net loss per share, basic and diluted (in dollars per share)

-3.81

-0.61

-0.25

-0.36

-14.89

-3.47

-0.57

-0.71

-0.60

-0.55

-0.46

-0.47

13.98

-5.46

-7.15

-6.22

-6.21

Weighted-average common shares outstanding, basic and diluted (in shares)

-37,224

6,061

26,877

23,112

-28,357

1,945

17,039

16,986

16,921

16,747

16,637

16,562

14,770

963

577

575

574